Generic Pharmaceutical Patent and FDA Law
Generic Pharmaceutical Patent and FDA Law covers Food and Drug Administration approval of generic drugs and the interaction of patents […]
Inside the mind of an EPO examiner
This article was originally published by Philippe Lahorte in World Patent Information Volume 54, Supplement, September 2018, Pages S18-S22 Under
See What Others are Saying About DrugPatentWatch
We thought you might be interested in some of the great reviews we’re getting over at software review site G2Crowd.
See What Others are Saying About DrugPatentWatch Read Post »
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded Generics: What They Are and Why They’re Profitable
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Branded Generics: What They Are and Why They’re Profitable Read Post »
Books
Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio
Kenneth L. Dorsney, Editor-in-Chief 1,035 pages Buy from Amazon Pre-ANDA litigation is the companion to ANDA Litigation, which I recommend
How Pharmaceutical Life Cycle Management Strategies Are Evolving
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
How Pharmaceutical Life Cycle Management Strategies Are Evolving Read Post »
Uncategorized
DrugPatentWatch in the news: The Biologic Patent Transparency Act.
For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as
DrugPatentWatch in the news: The Biologic Patent Transparency Act. Read Post »
![Fig 2. Sales for 8 medication-device combination products in 100-top sellers in the US from 2011–2013 [22]](https://www.drugpatentwatch.com/blog/wp-content/uploads/2019/03/Fig-2.-Sales-for-8-medication-device-combination-products-in-100-top-sellers-in-the-US-from-2011–2013-22-1024x1022.png)
Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products?
This paper was originally published by Reed F. Beall, Jason W. Nickerson, Warren A. Kaplan, Amir Attaran in PLoS ONE
Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products? Read Post »
